Ligand-Based Design

In our first miniWEBINAR of 2025 we were talking about a computational workflow to validate difficult-to-drug protein targets in "Opening up the druggable universe one cryptic pocket at a time" session presented by David LeBard, Head of Enhanced Sampling at OpenEye, Cadence Molecular Sciences,

Treeline Accelerates Discovery of Novel Therapeutics with Cadence’s Orion® on Millennium™ M2000 Supercomputer Over 800x speed-up on dedicated platform enables rapid, reliable drug design Cadence Molecular Sciences (OpenEye)—a business unit of Cadence (Nasdaq: CDNS)–is excited to announce the Orion® Molecular Design Platform is now available on the Cadence® Millennium™ M2000 Supercomputer in Cadence OnCloud, a state-of-the-art solution offering a tightly co-optimized software and hardware stack, that ensures drug discovery jobs run reliably and at scale.